Navigation Links
Generic Drugs: The Global Market--Focus on Asia
Date:9/22/2011

NEW YORK, Sept. 22, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Generic Drugs: The Global Market--Focus on Asia

http://www.reportlinker.com/p0619266/Generic-Drugs-The-Global-Market--Focus-on-Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

THIS REPORT CONTAINS

* An examination of the strategies employed by companies specializing in generics to meet the challenges of this highly competitive market as well as those utilized by "originator" companies to forestall generic competition; this report will focus on the markets in Asia

* Analyses of market trends, with data from 2010, estimates for 2011, and projections of compound annual growth rates (CAGRs) through 2016

* Discussion of how fierce price competition has put some companies in difficulties because of slashed profit margins, and of the resulting wave of merger-and-acquisition activity, and the rise of "supergenerics" that offer added value as well as low prices

* A breakdown of the nature and structure of the generics industry, with profiles of several leading generics companies, and an update of M&A activity

* Patent analyses.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide detailed market, technology, and industry analyses to help readers quantify and qualify the market for prescription generic drugs. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2016; these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the generic drug market. The wider economic environment is also taken into account.

The report examines strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by "originator" companies to forestall generic competition.

REASONS FOR DOING THE STUDY

This is a time of growth and change for the generic pharmaceuticals sector. Major aspects that combine to create an opportunity for an up-to-date market analysis include the following:

* The demand for generics is increasing steadily because of pressure to control healthcare costs. At the same time, fierce price competition in this area has created difficulties for some companies because of slashed profit margins. The main result has been a wave of merger and acquisition (M&A) activity, and the rise of "supergenerics," offering added value as well as low prices. Not all traditional companies are positioned to exploit this trend.

* A major growth driver for the generics sector is the fact that several blockbuster pharmaceutical brands are coming off-patent and are therefore open to generic competition—the phenomenon widely known as the "patent cliff." But the originator companies are deploying formidable strategies to protect their franchises, including marketing their own branded generics.

* With first-generation biopharmaceutical products reaching the end of their patent lives, a whole new market field—biogenerics or biosimilars—is opening up for those generics companies capable of (or prepared to buy-into) the technological expertise required.

* The international landscape is changing for generics as for all pharmaceuticals. China, India, Russia, Mexico, and Brazil are among the rising markets for generic activity.

SCOPE OF REPORT

This report discusses the implications of all the above-mentioned trends, in the context of the current size and growth of the generics market, both in global terms and analyzed by the most important national markets. The nature and structure of the generics industry is discussed, with profiles of the leading 20+ generics companies, and an update on M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

The report presents overall market size estimates and analysis for the overall global market, as well as more detailed market coverage of the three major segments of the global market: the American market, the European market, and the Asian market. The American market coverage focuses on the largest markets of North and Latin America (the U.S., Canada, Brazil, and Mexico); European market coverage focuses on the markets in France, Germany, Italy, Spain, and the United Kingdom, as well as an analysis of the Russian market; and Asia market coverage focuses on the three major markets of Japan, China, and India.

MARKET ANALYSES AND FORECASTS

Market figures are based on revenues at the manufacturer level and are projected based on 2011 dollar value without attempting to predict the effect of inflation/deflation.

Therapeutic categories quantified and forecast include antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g., hypolipidaemics and antihypertensives), and drugs for respiratory conditions, including asthma and COPD.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Primary research includes interviews with leading individuals in generics companies, industry associations, and regulatory bodies. Sources of published data include company annual reports, SEC filings, government and industry publications, literature searches, industry journals, and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, and are critically assessed by BCC Research.

INTENDED AUDIENCE

This report is designed to satisfy the information needs of a wide variety of individuals involved in the generics marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning, and sales departments who need readable, comprehensive, and up-to-date background on the marketplace in which they are operating.

INFORMATION SOURCES

Sources of information included marketing strategists, industry executives, government agencies and regulatory bodies, and surveys of physicians and pharmacists. Company annual reports and SEC filings, journal articles, and data from healthcare institutions were also mined, as well as publications of relevant trade associations such as the Generic Pharmaceutical Association (GPhA) and the European Generic Medicines Association (EGA).

CHAPTER ONE: INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

SCOPE OF REPORT 2

MARKET ANALYSES AND FORECASTS 2

METHODOLOGY 2

INTENDED AUDIENCE 3

INFORMATION SOURCES 3

ANALYST CREDENTIALS 3

RELATED REPORTS 3

BCC ONLINE SERVICES 4

DISCLAIMER 4

CHAPTER TWO: SUMMARY 5

SUMMARY 5

MARKET SIZE AND EVOLUTION 6

SUMMARY TABLE MAJOR GENERICS MARKETS, THROUGH 2016 ($

BILLIONS) 7

SUMMARY FIGURE MAJOR GENERICS MARKETS, THROUGH 2016

($ BILLIONS) 7

CHAPTER THREE: OVERVIEW 8

OVERVIEW 8

OVERVIEW (CONTINUED) 9

TABLE 1 GLOBAL PHARMACEUTICAL AND GENERICS MARKETS,

THROUGH 2016 ($ BILLIONS) 10

RECENT HISTORY OF THE GENERICS SECTOR 11

ROCHE-BOLAR 11

Roche-Bolar (Continued) 12

GENERICS LOBBY 13

ICH 14

CHAPTER FOUR: THE NEW GENERICS ERA 15

THE PATENT CLIFF 16

TABLE 2 FIRST PATENT EXPIRIES, 2012–2023 17

TYPES OF GENERICS 17

"SIMPLE" GENERICS 17

Factors Influencing the Success or Failure of Generics 18

Adequate Market Size 18

Patent-Expired Therapies 18

Older Products Still Used 19

Long-Term Use 19

Straightforward Production Technology 19

Drugs Used in Primary Care 20

SUPERGENERICS 20

BIOSIMILARS 21

Biosimilars (Continued) 22

TABLE 3 BIOLOGICS FACING THE LAUNCH OF BIOSIMILARS,

2001–2006 23

Special Challenges 24

Special Challenges (Continued) 25

The Biosimilar Market 26

Some Biosimilar Developments and Introductions 26

EPO 26

G-CSF 26

Interferons 26

HGH 27

Monoclonal Antibodies 27

Monoclonal … (Continued) 28

MAJOR GENERIC ISSUES 29

REGULATORY ENVIRONMENT 29

US 29

TABLE 4 REQUIREMENTS FOR NDA AND ANDA APPLICATIONS 30

US (Continued) 31

European Union 32

EU Marketing Authorization Systems 32

The Centralized Procedure 33

Decentralized and Mutual Recognition

Procedures 34

Mutual-Recognition Procedure 34

Types of Applications 35

Applications Under Article 10 (Generic

Products) 35

Japan 36

Approval (Shonin) of Pharmaceuticals 37

REGULATION OF BIOSIMILARS 37

EU Provisions 38

Evolving Situation in the US 39

Hatch-Waxman and Bolar 39

Defensive Strategies by "Big Pharma" 40

"AUTHORIZED GENERICS" 41

User Fees 42

A "Mood Swing" Toward Generics 43

The Situation in Europe 44

PATENTS AND IP 45

SUPPLEMENTARY PROTECTION CERTIFICATES 46

Supplementary Protection Certificates (Continued) 47

CHAPTER FIVE: THE GLOBAL PHARMACEUTICAL AND GENERICS

MARKET 48

GLOBAL GENERICS MARKET 48

MAIN NATIONAL GENERICS MARKETS 49

TABLE 5 WORLD PHARMA AND GENERICS MARKETS, THROUGH

2016 ($ BILLIONS) 49

TABLE 6 CURRENT AND FORECAST NATIONAL GENERICS

MARKETS, THROUGH 2016 ($ BILLIONS) 50

MARKET OPPORTUNITIES BY PRODUCT CLASS 50

LEADING GENERIC MOLECULES 50

TABLE 7 WIDELY PRESCRIBED GENERIC MOLECULES IN THE US

AND EUROPE 50

TABLE 7 (CONTINUED) 51

Anti-infectives 51

Anti-infectives (Continued) 52

TABLE 8 LEADING ANTI-INFECTIVE PRODUCTS SALES

ESTIMATES WITH YEAR OF PATENT EXPIRY, 2010 ($ BILLIONS) 53

CNS Therapies 54

TABLE 9 CNS MARKET BY MAJOR INDICATIONS, 2010 ($

BILLIONS) 54

FIGURE 1 CNS MARKET SHARES BY MAJOR INDICATIONS, 2010

(%) 55

Antidepressants 55

Antipsychotics 56

TABLE 10 LEADING CNS PRODUCT SALES ESTIMATES, 2010 ($

BILLIONS) 57

Anxiolytics 57

Sleep Disorders 58

Epilepsy 58

Parkinson's Disease 59

Migraine 59

Cardiovascular Products 60

TABLE 11 LEADING CARDIOVASCULAR PRODUCT SALES, 2009 ($

BILLIONS) 61

Anti-arthritis Products 62

Steroids 62

NSAIDs 63

COX- II Inhibitors 63

DMARDs 64

TABLE 12 LEADING ANTI-ARTHRITIS PRODUCT SALES

ESTIMATES, 2009 ($ BILLIONS) 65

Respiratory Products 66

Asthma 66

COPD 66

Allergic Rhinitis 67

Allergic … (Continued) 68

TABLE 13 LEADING RESPIRATORY PRODUCT SALES ESTIMATES,

2009 ($ BILLIONS) 69

Drugs Used to Treat Asthma and COPD 69

Bronchodilators 69

Inhaled Bronchodilators 69

Anticholinergics 70

Oral Bronchodilators 70

Leukotriene Antagonists 70

Steroids 71

FIGURE 2 USAGE OF MAIN PRODUCT CATEGORIES BASED

REVENUES (%) 71

FIGURE 2 (CONTINUED) 72

Anticancer Products 72

Cytotoxic Drugs 72

Hormonal Therapy 72

Biologic Response Modifiers 73

Antiangiogenesis Drugs 73

Monoclonal Antibodies 73

TABLE 14 LEADING ANTICANCER PRODUCT SALES ESTIMATES,

2009 ($ BILLIONS) 74

Monoclonal Antibodies (Continued) 75

CHAPTER SIX: THE ASIAN REGION 76

JAPAN 76

VITAL STATISTICS 76

HEALTH AND HEALTHCARE 76

PHARMACEUTICAL MARKET 77

TABLE 15 TOP 5 JAPANESE PHARMA COMPANIES, 2008 (%) 78

GENERICS SECTOR 79

Foreign Presence 80

Market Resistance 81

Generics Industry 82

TABLE 16 JAPANESE PHARMACEUTICAL AND GENERICS

MARKET, 2011–2016 ($ BILLIONS) 83

INDIA 83

VITAL STATISTICS 83

HEALTH AND HEALTHCARE 83

Growing Affluence—Changing Medical Needs 84

Regulatory Changes 84

PHARMACEUTICAL MARKET 84

Demographic Factors 85

Pharma Industry 85

Patent Reform 86

GENERICS INDUSTRY 87

TABLE 17 LEADING PHARMA COMPANIES IN INDIA, 2010 ($

MILLIONS) 87

TABLE 18 PHARMACEUTICAL AND GENERICS MARKET IN INDIA,

THROUGH 2016 ($ BILLIONS) 88

CHINA 88

VITAL STATISTICS 88

HEALTH AND HEALTHCARE 88

Health and Healthcare (Continued) 89

PHARMACEUTICAL MARKET 90

Domestic Industry 91

Foreign Company Involvement 92

Importance of R&D 93

Challenges 94

Market Trends 94

Regulatory Changes 95

Generic Exports 95

Domestic Generics Market 96

Local Dominance 97

FIGURE 3 GENERICS MARKET THERAPEUTIC CATEGORIES 2008

(%) 98

TABLE 19 PHARMACEUTICAL AND GENERICS MARKET, CHINA,

THROUGH 2016 ($ BILLIONS) 99

CHAPTER SEVEN: PROFILES OF THE TOP TEN GENERICS

COMPANIES 100

TABLE 20 LEADING GENERICS MANUFACTURERS, 2010 ($

BILLIONS/%) 100

TRENDS 100

STRUCTURE OF THE GENERICS INDUSTRY 101

PROFILES OF TOP 10 GENERICS COMPANIES 102

ACTAVIS 102

Actavis (Continued) 103

APOTEX INC 104

DR REDDY'S LABORATORIES, LTD 105

Acquisitions 106

Financials 107

HOSPIRA, INC 107

Biogenerics 108

Financials 109

MYLAN INC 109

Mylan Inc (Continued) 110

Financials 111

Looking Ahead 111

PAR PHARMACEUTICAL, INC 111

Generics 112

Financials 112

RANBAXY LABORATORIES, LTD 113

History 113

Acquisition by Daiichi Sankyo 114

Financials 115

Looking Ahead 115

SANDOZ INTERNATIONAL GMBH 116

Products 116

TEVA PHARMACEUTICAL INDUSTRIES, LTD 117

Teva Pharmaceutical Industries, Ltd (Continued) 118

Financials 119

WATSON PHARMACEUTICALS, INC 120

Products 120

Financials 120

Looking Ahead 121

CHAPTER EIGHT: PROFILES OF OTHER INTERNATIONAL GENERICS

COMPANIES 122

PROFILES 122

ALAPIS GROUP 122

AMNEAL PHARMACEUTICALS, LLC 123

Amneal Pharmaceuticals Co India Pvt, Ltd 123

ASPEN PHARMACARE HOLDINGS, LTD 124

Financial Results 125

AUROBINDO PHARMA, LTD 126

Products 126

Financials 127

Looking Ahead 127

BERLIN-CHEMIE AG 127

BIOCON 128

Biocon US 128

Biocon US (Continued) 129

Biocon US (Continued) 130

BIOGARAN FRANCE 131

CIPLA, LTD 132

COBALT 133

EGIS PHARMACEUTICALS, PLC 134

APIs 135

Pharmaceutical R&D 135

GEDEON RICHTER, PLC 136

GENEPHARM GROUP 137

KRKA, DD, NOVO MESTO 138

Products 139

Financials 140

Looking Ahead 140

KV PHARMACEUTICAL CO 140

LUPIN, LTD 140

Lupin, Ltd (Continued) 141

MITSUBISHI TANABE PHARMA CORP 142

Tanabe Seiyaku Hanbai Co, Ltd 142

NICHI-IKO PHARMACEUTICAL CO, LTD 143

Products 143

Financials 144

Looking Ahead 144

NIPPON CHEMIPHAR CO, LTD 144

Financials 145

Looking Ahead 145

NOVARTIS INTERNATIONAL AG 145

Looking Ahead 146

ORION CORP 146

Products 146

Generics 147

Financials 147

Looking Ahead 147

PFIZER INC 147

US Basic Patent Expiry 148

TABLE 21 PFIZER'S US PATENT EXPIRIES, THROUGH 2021 148

Financials 149

PLIVA DD 149

ROXANE LABORATORIES, INC 150

SANOFI-AVENTIS 151

Looking Ahead 152

SAWAI PHARMACEUTICAL 152

Products 153

Financials 153

Looking Ahead 153

STADA ARZNEIMITTEL 154

Generics 154

Biosimilars 155

Financials 155

Looking Ahead 155

STRIDES ARCOLAB, LTD 156

Product Range 157

Looking Ahead 157

WOCKHARDT, LTD 158

Financials 159

Looking Ahead 159

ZYDUS CADILA 160

Zydus US Corporate Office 160

Zydus US … (Continued) 161

To order this report:

In Vitro Diagnostic Industry: Generic Drugs: The Global Market--Focus on Asia

In Vitro Diagnostic Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Generic Drugs: The Global Market
2. Generic Drugs: The Global Market: Focus on the Americas
3. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
4. Actavis Launches Generic Keppra XR® Tablets in the U.S.
5. Lupin Announces Launch of Generic KEPPRA XR® Tablets
6. European Fine Chemicals Group Ratifies FDAs Proposed Generic Drug User Fees Act (GDUFA)
7. Lupin Receives Final Approval to Market Generic Ultram® ER
8. Media Advisory: Interview Source for Story About Plea to FDA to Allow Generic Drug Makers to Update Labels
9. Managing Bioequivalence Studies to Optimize the Quality, Cost, and Speed of Generics Manufacturing
10. Simceres Branded Generic Formulation Biqi Passes EU-GMP Inspection
11. Prasco® Launches Authorized Generic with Shionogi Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
Breaking Medicine News(10 mins):